Last reviewed · How we verify
Treatment with Amikacin
Amikacin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death.
Amikacin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death. Used for Serious gram-negative bacterial infections, Nosocomial infections caused by susceptible organisms, Septicemia.
At a glance
| Generic name | Treatment with Amikacin |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amikacin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, disrupting accurate mRNA translation and causing misreading of the genetic code. This results in production of non-functional proteins and ultimately bacterial cell death. It is bactericidal and effective against a broad spectrum of gram-negative aerobic bacteria and some gram-positive organisms.
Approved indications
- Serious gram-negative bacterial infections
- Nosocomial infections caused by susceptible organisms
- Septicemia
- Respiratory tract infections
- Urinary tract infections
- Intra-abdominal infections
Common side effects
- Nephrotoxicity (acute kidney injury)
- Ototoxicity (hearing loss, tinnitus, vertigo)
- Neuromuscular blockade
- Injection site reactions
- Rash
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin (PHASE2)
- Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
- Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia (PHASE4)
- Model-Informed Precision Dosing on Amikacin and Vancomycin Therapy in Critically Ill Children (NA)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment with Amikacin CI brief — competitive landscape report
- Treatment with Amikacin updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI